Shuttle Pharmaceuticals Holdings, Inc. · NASDAQ:SHPH
Shuttle Pharmaceuticals — Investor Presentation (August 2024)
15 slides from Shuttle Pharmaceuticals's investor presentation, Aug 15, 2024
Slide 1: Shuttle Pharmaceuticals Holdings, Inc. Investor Presentation
Shuttle Pharmaceuticals Holdings, Inc. Nasdaq: SHPH Investor Presentation August 2024
Slide 2: Forward Looking Statements
Forward Looking Statements All of the information contained within this business presentation (the “Presentation”) has been obtained from sources generally believed to be reliable by Shuttle Pharmaceuticals Holdings, Inc. (referred to herein as “Shuttle Pharmaceuticals,” “Shuttle Pharma” or the “Com
Slide 3: The Fundamental Problem of Radiation Therapy
The Fundamental Problem of Radiation Therapy: Cancers are surrounded by radiation sensitive, dose-limiting normal tissues Sensitization of cancer cells to radiation therapy ▪ The radiation dose determines cancer curability ▪ Adjacent normal tissues are dose-limiting Sensitizer ▪ Radiation sensitizer
Slide 4: Company Overview
Company Overview Shuttle Pharma (Nasdaq: SHPH) is a clinical-stage pharmaceutical company, developing next generation drugs and diagnostics to improve outcomes for cancer patients treated with radiation therapy (RT). Therapeutics ▪ Ropidoxuridine is a clinical stage, orally-administered cancer radia
Slide 5: Radiation Sensitization, Immune Modulation, Diagnostics and Theranostics
Radiation Sensitization Cancer resistance to cure by radiation therapy, due to limitations presented by adjacent radiation sensitive normal tissues, can be overcome by Ropidoxuridine + RT Radiation Sensitization and Immune Modulation Selective HDAC6 inhibitors stimulate the innate immune system targ
Slide 6: Ropidoxuridine (IPdR) – How does it work?
Ropidoxuridine (IPdR) – How does it work? Ropidoxuridine (IPdR) is the prodrug of IUdR Ropidoxuridine (IPdR) is metabolized to ▪ IUdR is a powerful radiation sensitizer showing Phase II efficacy in NIH sponsored clinical IUdR, incorporates into DNA, and trials in glioblastoma, anaplastic astrocytoma
Slide 7: Ropidoxuridine (IPdR) – Clinical Asset Development
Ropidoxuridine (IPdR) – Clinical Asset Development ▪ Phase I and pharmacology study of Ropidoxuridine (IPdR) and RT (Clin Cancer Res, 2019). ▪ 18 patients reached an MTD of Ropidoxuridine with RT of 1200 mg daily for 28 days ▪ 14 patients were assessed for tumor responses: 4 partial responses, 9 sta
Slide 8: Ropidoxuridine (IPdR) – Phase II Update
Ropidoxuridine (IPdR) – Phase II Update Phase II study of Ropidoxuridine + RT . “Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH- Wildtype Glioblastoma With Unmethylated MGMT Promoter” - ClinicalTrials.gov ID NCT06359379 ▪ Drug product (API) has been manufactured by TCG GreenChem and form
Slide 9: Pre-clinical Asset Development: Selective HDAC6 Inhibitor SP-2-225
Pre-clinical Asset Development: Selective HDAC6 Inhibitor SP-2-225 How does it work? SP-2-225 inhibits HDAC6, prolongs macrophage polarization in M-1 state, resulting in an enhanced inflammatory response to immunogenic cancers and Acetylated histones Irradiated tumors. Active transcription The next
Slide 10: Intellectual Property
Intellectual Property Ropidoxuridine (radiation sensitizers) ▪ Orphan disease designation, method od use patent for next generation IPdR/TPI formulation. Selective HDAC inhibitors (radiation sensitizers/immune modulators) ▪ > 20 composition of matter HDAC inhibitor patents in the U.S., Canada and Eu
Slide 11: Clinical Development Strategy - Priorities
Clinical Development Strategy - Priorities THERAPEUTICS ▪ Therapy Priority #1: Clinical development of Ropidoxuridine & RT ▪ Perform the Phase II clinical trial of Ropidoxuridine & RT in brain tumors ▪ Seek FDA “breakthrough” designation and early marketing approval on glioblastoma ▪ Prepare Ropidox
Slide 12: Financial Overview
Financial Overview Shuttle Pharmaceuticals Capital Market Profile Cap Table as of March 31, 2024 Common Stock 16,819,893 Exchange/Ticker NASDAQ: SHPH Fully Vested Restricted Stock Units (RSUs) 125,000 Closing Stock Price* $0.42 RSUs Outstanding 272,855 52 Wk High/Low* $0.35 - $2.75 Warrants Outstand
Slide 13: Shuttle's Experienced Leadership Team
Shuttle’s Experienced Leadership Team ▪ Founder & CEO of Shuttle ▪ President & COO of ▪ VP Regulatory Pharma since 2012; Chairman, Shuttle Pharma 2012 Shuttle Pharma 2012 Board of Directors 2017 ▪ CFO Shuttle Pharma ▪ CFO Shuttle Pharma ▪ Former Member, Board of 2012-2019 2019 - 2024 Directors, Neop
Slide 14: Board of Directors
Board of Directors Steve Richards, MBA, CPA Milton Brown, MD, PhD Bette Jacobs, PhD Chris Senanayake, PhD Joshua Schafer, MBA Chief Commercial Officer Businessman Vice Dean for Research Professor/Distinguished Scholar CEO, TCG GreenChem & EVP of Business Development CEO, Endurance Media East Virgini
Slide 15: Thank You
THANK YOU Shuttle Pharmaceuticals Holdings, Inc. Anatoly Dritschilo, MD, CEO Tel: (240) 403-1212 Email: anatoly.dritschilo@ShuttlePharma.org Investor Relations Lytham Partners Robert Blum Tel: (602) 889-9700 Email: SHPH@LythamPartners.com
Shuttle Pharmaceuticals Holdings — Investor Presentation (August 2024) on 6ix